Detalhe da pesquisa
1.
α-FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma.
Int J Cancer
; 154(6): 1043-1056, 2024 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37994647
2.
Accuracy of the Enhanced Liver Fibrosis Test in Patients With Type 2 Diabetes Mellitus and Its Clinical Implications.
Clin Gastroenterol Hepatol
; 22(4): 789-797.e8, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38048934
3.
Regional Differences in Clinical Presentation and Prognosis of Patients With Post-Sustained Virologic Response Hepatocellular Carcinoma.
Clin Gastroenterol Hepatol
; 22(1): 72-80.e4, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37442316
4.
Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phase.
Hepatology
; 78(5): 1558-1568, 2023 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37184202
5.
Ramucirumab for advanced hepatocellular carcinoma in the current real world: a Japanese single-arm study post-REACH-2 (The R-evolution study).
Invest New Drugs
; 2024 Jun 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38842657
6.
Comparison of prognostic impact of atezolizumab plus bevacizumab versus lenvatinib in patients with intermediate-stage hepatocellular carcinoma.
Liver Int
; 44(1): 113-124, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37789669
7.
Impact of body mass index on the prognosis of unresectable HCC patients receiving first-line Lenvatinib or atezolizumab plus bevacizumab.
Liver Int
; 44(5): 1108-1125, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38517286
8.
Kinetics of the hepatitis B core-related antigen and treatment responses in chronic hepatitis B patients treated with tenofovir alafenamide.
Hepatol Res
; 2024 Apr 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38685853
9.
Comparative analysis of the therapeutic outcomes of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma patients aged 80 years and older: Multicenter study.
Hepatol Res
; 54(4): 382-391, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-37983642
10.
Comparison of six hepatocellular carcinoma prediction models in Japanese patients after sustained virologic response undergoing rigorous surveillance for hepatocellular carcinoma.
J Gastroenterol Hepatol
; 39(5): 949-954, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38291715
11.
Mortality in patients with chronic hepatitis B treated with tenofovir or entecavir: A multinational study.
J Gastroenterol Hepatol
; 2024 Mar 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-38480009
12.
Clinical effects and emerging issues of atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma from Japanese real-world practice.
Cancer
; 129(4): 590-599, 2023 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36426410
13.
Poor Diagnostic Efficacy of Noninvasive Tests for Advanced Fibrosis in Obese or Younger Than 60 Diabetic NAFLD patients.
Clin Gastroenterol Hepatol
; 21(4): 1013-1022.e6, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35654298
14.
Comparison between Atezolizumab Plus Bevacizumab and Lenvatinib for Hepatocellular Carcinoma in Patients with Child-Pugh Class B in Real-World Clinical Settings.
Oncology
; 101(9): 542-552, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37552968
15.
Nutritional Status Is Associated with Prognosis in Patients with Advanced Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab.
Oncology
; 101(4): 270-282, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36455517
16.
Lenvatinib as Second-Line Treatment after Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma: Clinical Results Show Importance of Hepatic Reserve Function.
Oncology
; 101(10): 624-633, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37307798
17.
Role of the Prognostic Nutritional Index in Predicting Survival in Advanced Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab.
Oncology
; 101(5): 283-291, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36657420
18.
Hyperprogressive disease during atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma from Japanese real-world practice.
BMC Gastroenterol
; 23(1): 101, 2023 Mar 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-37003980
19.
Japanese subgroup analysis of GLIMMER: A global Phase IIb study of linerixibat for the treatment of cholestatic pruritus in patients with primary biliary cholangitis.
Hepatol Res
; 53(7): 629-640, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-36852705
20.
Cell-free and concentrated ascites reinfusion therapy versus large-volume paracentesis for the treatment of cirrhotic patients with refractory ascites: A multicenter prospective observational study.
Hepatol Res
; 53(3): 238-246, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-36433862